Adaptive, randomized, investigator-masked Phase 2 study of RO5093151 in ocular hypertension and primary open angle glaucoma

Phase 2, randomised, single-blind trial of RO5093151 in open-angle glaucoma (OAG) and ocular hypertension, sponsored by Roche. Primary endpoint: Change from baseline in mean intraocular pressure at 1 hour post-dose after 7 days of treatment. Started Nov 2011; status: terminated.